Literature DB >> 8497455

Mechanism of action of fibrates.

J Shepherd1.   

Abstract

Fibrates are effective in hypertriglyceridaemia and hypercholesterolaemia. They affect both triglyceride-rich and cholesterol-rich particles and have at least four separate modes of action. These include limitation of substrate availability for triglyceride synthesis in the liver; promotion of the action of lipoprotein lipase; modulation of low density lipoprotein (LDL) receptor/ligand interaction and stimulation of reverse cholesterol transport. Studies of LDL metabolism suggest the existence of two separate catabolic pathways involving the LDL receptor and scavenger mechanism(s). The former route is anti-atherogenic; the latter pro-atherogenic. At low triglyceride levels, the fractional clearance of LDL by the receptor is high. The action of fibrates is to promote the secretion of LDL which is cleared by a receptor-mediated mechanism. Catabolism of this fraction increases from 40% of the plasma pool per day in untreated to 60% per day in treated subjects. By activating lipoprotein lipase, fibrates also reduce the amount of small dense LDL, the fraction which is most likely to generate peroxidation products. Hence, fibrates stimulate LDL receptor-dependent clearance mechanisms and reduce the amount of LDL available for oxidation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497455

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  7 in total

Review 1.  Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.

Authors:  J C Adkins; D Faulds
Journal:  Drugs       Date:  1997-10       Impact factor: 9.546

Review 2.  Statins: is there a need for alternative or adjunctive therapy?

Authors:  J Shepherd
Journal:  Br Heart J       Date:  1995-07

3.  Pharmacological effects of lipid-lowering drugs on circulating adipokines.

Authors:  Desiree Wanders; Eric P Plaisance; Robert L Judd
Journal:  World J Diabetes       Date:  2010-09-15

4.  Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.

Authors:  Leigh Perreault; Bryan C Bergman; Devon M Hunerdosse; David J Howard; Robert H Eckel
Journal:  Metabolism       Date:  2011-02-08       Impact factor: 8.694

Review 5.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

6.  Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.

Authors:  Michael H Davidson; Peter H Jones
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Manufacturing nanosized fenofibrate by salt assisted milling.

Authors:  Vadym N Mochalin; Adarsh Sagar; Shruti Gour; Yury Gogotsi
Journal:  Pharm Res       Date:  2009-02-18       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.